Ken Chang, Ph.D.

Dr. Chang was the founder, the President, CEO and Chairman of the Board of former Ardent Pharmaceuticals, Inc., Durham, North Carolina. He has raised approximately $35 million since the inception of Ardent Pharmaceuticals in 1995. Ardent Pharmaceuticals, Inc. was recently merged with Enhance Biotech, Inc., a public company. Dr. Chang’s new title for the Enhance Biotech, Inc. is the Chief Scientific Officer and President Asia-Pacific Operations. He currently holds an Adjunct Professor appointment in the Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina.

He was a Principal Scientist at former Burroughs Wellcome Co. He is the co-inventor for 8 issued US patents and 8 pending US patents. Dr. Chang has published approximately 200 papers. He is a co-editor of the book entitled “The Delta Receptor” published by Marcel Dekker, Inc. in 2004. He is an internationally recognized expert in receptor pharmacology, biochemistry and molecular biology. He pioneered in the discovery of delta receptors, delta receptor-selective compounds and the understanding of physiological functions of the delta receptors. Dr. Chang received his Bachelor of Science degree in Pharmacy from the School of Pharmacy, National Taiwan University in Taipei, Taiwan and his Ph.D. degree in Biochemical Pharmacology from the State University of New York at Buffalo, and his postdoctoral training in Medical School, Johns Hopkins University.